title: [Recurrent esophageal cancer with complete response to TS-1 chemotherapy].
abstract: An 80-year-old man was admitted to our hospital for treatment of recurrent esophageal cancer in December, 2004. He was diagnosed as having esophageal cancer of stage IVa (T2N4M0) in October, 2002, and he received chemoradiotherapy (nedaplatin (CDGP)/5-fluorouracil (5-FU) total 6 course+60 Gy). Afterwards, lymph nodes recurred, and two courses of CDGP/vindesine were given. Then, the primary lesion showed a complete response (CR), and lymph nodes a partial response (PR). In December, 2004, paraesophageal lymph nodes were enlarged to the size of 7 cm. On admission, because of renal disturbance and dementia with advanced age, we chose chemotherapy with TS-1 (100 mg/body/day, three weeks of administration, then two weeks of withdrawal). He had adverse effects of hematotoxicity of grade 3, and non-hematotoxicity of grade 1. He received 6 courses of this regimen and eventually showed CR. Serum SCC was decreased from 4.7 ng/mL to 0.9 ng/mL. At present,the lesions have not recurred during the follow-up for 18 months.
authors.affiliation: The First Dept. of Internal Medicine, University of the Ryukyus.
authors.forename: Takako
authors.initials: T
authors.lastname: Watanabe
authors.forename: Takayuki
authors.initials: T
authors.lastname: Chinen
authors.forename: Norishige
authors.initials: N
authors.lastname: Nakachi
authors.forename: Manabu
authors.initials: M
authors.lastname: Nakamoto
authors.forename: Nobufumi
authors.initials: N
authors.lastname: Uchima
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Hirata
authors.forename: Akira
authors.initials: A
authors.lastname: Hokama
authors.forename: Nagisa
authors.initials: N
authors.lastname: Kinjo
authors.forename: Fukunori
authors.initials: F
authors.lastname: Kinjo
authors.forename: Jiro
authors.initials: J
authors.lastname: Fujita
mesh_terms: D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D011788:Quality of Life; D012074:Remission Induction; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid